000129069 001__ 129069
000129069 005__ 20240228143407.0
000129069 0247_ $$2doi$$a10.18632/oncotarget.10035
000129069 0247_ $$2pmid$$apmid:27322425
000129069 0247_ $$2pmc$$apmc:PMC5190099
000129069 037__ $$aDKFZ-2017-05074
000129069 041__ $$aeng
000129069 082__ $$a610
000129069 1001_ $$0P:(DE-He78)3d0bd280b309d8ef615f728f271a8595$$aLöffler, Harald$$b0$$eFirst author$$udkfz
000129069 245__ $$aMolecular driver alterations and their clinical relevance in cancer of unknown primary site.
000129069 260__ $$a[S.l.]$$bImpact Journals LLC$$c2016
000129069 3367_ $$2DRIVER$$aarticle
000129069 3367_ $$2DataCite$$aOutput Types/Journal article
000129069 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524821433_12271
000129069 3367_ $$2BibTeX$$aARTICLE
000129069 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000129069 3367_ $$00$$2EndNote$$aJournal Article
000129069 520__ $$aCancer of unknown primary (CUP) is defined as metastatic solid malignancy where no primary tumor is detected despite appropriate staging. About 90% of CUP represent adenocarcinoma or undifferentiated carcinoma. Since therapy regimens are only modestly effective, identification of the molecular landscape of these neoplasms might be a promising approach to direct CUP therapy and aid in tumor classification. We screened a cohort of 128 patients with adenocarcinoma or undifferentiated carcinoma meeting the definition of CUP. Massive parallel multigene sequencing of 50 genes, which had been selected due to their relevance as oncogenic drivers or druggable molecular targets could ultimately be performed on samples from 55 patients for whom complete clinical datasets were also available. Overall, 60 tumor-specific mutations and 29 amplifications/deletions, as revealed by coverage analysis, were detected in 46 cases (84%). The most frequently mutated genes were TP53 (30 cases, 55%), KRAS (9 cases, 16%), CDKN2A (5 cases, 9%), and SMAD4 (5 cases, 9%). The most frequently deleted gene was CDKN2A (8 cases, 15%). KRAS and CDKN2A mutations significantly correlated with poor progression-free survival (PFS) and, in case of KRAS, overall survival (OS). WIldtype TP53 and female sex defined a relatively favorable category, with favorable PFS and OS. 8 cases (15%) harbored mutations that may be targetable by currently approved drugs. Taken together, Mutations of relevant driver genes are present in the vast majority of CUP tumors. Some of them impact on prognosis and a subset is putatively druggable.
000129069 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000129069 588__ $$aDataset connected to CrossRef, PubMed,
000129069 7001_ $$aPfarr, Nicole$$b1
000129069 7001_ $$aKriegsmann, Mark$$b2
000129069 7001_ $$aEndris, Volker$$b3
000129069 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b4$$udkfz
000129069 7001_ $$aLohneis, Philipp$$b5
000129069 7001_ $$aFolprecht, Gunnar$$b6
000129069 7001_ $$aStenzinger, Albrecht$$b7
000129069 7001_ $$aDietel, Manfred$$b8
000129069 7001_ $$0P:(DE-HGF)0$$aWeichert, Wilko$$b9
000129069 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b10$$eLast author$$udkfz
000129069 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.10035$$gVol. 7, no. 28, p. 44322 - 44329$$n28$$p44322 - 44329$$tOncoTarget$$v7$$x1949-2553$$y2016
000129069 909CO $$ooai:inrepo02.dkfz.de:129069$$pVDB
000129069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d0bd280b309d8ef615f728f271a8595$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000129069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000129069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000129069 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000129069 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000129069 9141_ $$y2016
000129069 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000129069 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000129069 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000129069 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000129069 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000129069 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000129069 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000129069 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000129069 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000129069 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000129069 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000129069 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000129069 9201_ $$0I:(DE-He78)L701-20160331$$kL701$$lDKTK München$$x3
000129069 9201_ $$0I:(DE-He78)L201-20160331$$kL201$$lDKTK Berlin$$x4
000129069 9201_ $$0I:(DE-He78)L301-20160331$$kL301$$lDKTK Dresden$$x5
000129069 980__ $$ajournal
000129069 980__ $$aVDB
000129069 980__ $$aI:(DE-He78)G330-20160331
000129069 980__ $$aI:(DE-He78)C060-20160331
000129069 980__ $$aI:(DE-He78)L101-20160331
000129069 980__ $$aI:(DE-He78)L701-20160331
000129069 980__ $$aI:(DE-He78)L201-20160331
000129069 980__ $$aI:(DE-He78)L301-20160331
000129069 980__ $$aUNRESTRICTED